Targovax ASA NOK0.10
Targovax ASA NOK0.10
-2,82 %
5,510 NOK
-0,16
Noter.
5,510
Høy
5,700
Endring
-2,82 %
Lav
5,260
Oppdatert
24.05.2019
Åpen
5,690
Factsheet for Targovax ASA NOK0.10
Company Profile
Description
Targovax ASA is a clinical stage company. It is focused on developing and commercializing immuno-oncology therapies to target treatment-resistant solid tumors. The firm's proprietary platforms include ONCOS and TG peptides.
Key Stats
Website: https://www.targovax.com
Headquarter country: Norway
Employees: 4
Market Cap (at close 24.05.2019): NOK 348M
Fiscal Year Ends: desember
Stats

Stats 2018 2017 2016 2015 2014
Price/Earnings
Forward Price/Earnings
Price/Free Cash Flow
Return on Assets -22,90 -33,10 -43,30
Return on Equity -29,70 -41,90 -57,90
Return on Invested Capital -26,50 -36,20 -50,40
Dividend


Dividend/Share:
Ex. Dividend Date:01.01.0001
Trailing Dividend Yield:
Payout Ratio:0,00
Date Currency Amount
Income Statement

Revenue 2018 2017 2016 2015 2014
Total Revenue 0,04 0,07
Gross Profit -0,01
Gross Margin % -8 613,04%
Operating Expenses 2018 2017 2016 2015 2014
EBITDA -119,00 -98,00 -18,00
Net income -122,00 -101,00 -18,00
Basic Earnings Per Share -3,41 -2,34 -2,28
Operating Income -0,12 -0,10 -0,02
Operating Margin % -323 000,00% -24 237,45%
Cash Flow

Cash Flow 2018 2017 2016 2015 2014
Operating Cash Flow -110,00 -81,00 -14,00
Capital Expenditures 0,00 0,00 0,00
Free Cash Flow -110,00 -81,00 -14,00
Balance Sheet

Assets 31.12.2018 31.12.2017 31.12.2016 31.12.2015 31.12.2014
Current Assets 185,83 185,46 67,21
Long Term Assets 339,51 359,66 0,15
Total Assets 525,35 545,11 67,36
Liabilities 31.12.2018 31.12.2017 31.12.2016 31.12.2015 31.12.2014
Total Current Liabilities 29,19 25,42 6,69
Long Term Liabilities 94,99 96,82
Total Liabilities 124,18 122,24
Equity 31.12.2018 31.12.2017 31.12.2016 31.12.2015 31.12.2014
Retained Earnings -253,52 -131,07 -38,84
Treasury Stock
Total Stockholder Equity 401,17 422,87 60,67
Net Tangible Assets 62,95 64,80 60,67